Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado 80523
Received 25 July 2003/ Returned for modification 2 September 2003/ Accepted 11 September 2003
| ABSTRACT |
|---|
|
|
|---|
| TEXT |
|---|
|
|
|---|
Theoretically, if the M. tuberculosis infection is latent, then one would expect reactive T cells in the lung lesions to be in a state of memory, as can indeed be observed if the infection is cleared by drugs (1). However, other models of immunological memory, particularly those following more acute viral infections, have provided convincing evidence that the differentiation of naïve T cells into effector cells and subsequently into memory immune cells is a tightly controlled process (15, 16). A central determining factor is the availability of antigen, and it has been suggested by Bevan (2) that the transition of T cells from effector to memory would be unlikely in a situation such as chronic tuberculosis, where a source of antigen persists.
To address the issue of antigen persistence and its influence on the activation state of T cells during a pulmonary tuberculosis infection, T cells were harvested from the lungs of mice chronically infected with M. tuberculosis and then analyzed for their cell surface molecule expression. Throughout the chronic stage of infection, the majority of cells consistently exhibited a phenotype consistent with that of effector T cells. The data suggest that some surviving M. tuberculosis bacilli may slowly and continuously replicate during the chronic stage of infection, thus providing sufficient antigen to maintain the T-cell population in the lung lesions in a state of effector immunity.
Mice and bacterial strain. C57BL/6 mice, 8 to 10 weeks old, were purchased from Jackson Laboratories, Bar Harbor, Maine. M. tuberculosis strain Erdman was grown to mid-log phase in Proskauer-Beck liquid medium containing 0.05% Tween 80 and then frozen in aliquots at -70°C until needed. Mice were infected by aerosol exposure procedures described previously (5, 6).
Lung cells and flow cytometry. In order to obtain single-cell suspensions from the lungs, the organs were treated and processed strictly as described previously (11, 12). Cells were labeled with the following specific antibodies: fluorescein isothiocyanate (FITC) anti-CD44, phycoerythrin anti-CD45RB or anti-CD122, peridinin chlorophyll a protein anti-CD8 or anti-CD4, and allophycocyanin anti-CD62L. All antibodies were purchased from BD Pharmingen and were used at a concentration 0.2 µg per 106 cells in phosphate-buffered saline for 30 min at 4°C. The cells were analyzed on a Becton Dickinson FACScalibur and the data were analyzed with CellQuest software (Becton Dickinson Immmunocytometry Systems, San Jose, Calif.). All the analyses were done with an acquisition of 100,000 events.
Specific immune response.
Bone marrow macrophages (2 x 105 cells/ml) were either infected with 2.5 x 106 CFU of M. tuberculosis Erdman per ml in a final volume of 1 ml of complete Dulbecco minimum essential medium or pulsed with culture filtrate protein from M. tuberculosis (10 µg/ml; supplied by John T. Belisle) for 4 h. The plates were incubated for 18 h at 37°C in 5% CO2 with lung cell suspensions of control age-matched or infected mice. For the final 6 h of the incubation period, 3 µM monensin (Golgi Stop; BD Pharmingen) was added to the cultures. The lung cells were labeled with allophycocyanin anti-CD4 and peridinin chlorophyll a protein anti-CD8 and fixed and permeabilized according to the manufacturer's directions with a Golgi Stop kit (BD Pharmingen); cells were then stained for intracellular FITC anti-gamma interferon (IFN-
) or FITC rat immunoglobulin G1 isotype control (BD Pharmingen). The samples were analyzed by flow cytometry.
IHC analysis. In order to execute an immunohistochemical (IHC) analysis for CD4 and CD8 T cells, the right first lobe from each mouse was collected. The IHC analysis was done as previously described (11). All experiments were performed three times, and statistical significance between the different groups was determined using the Student t test.
Maintenance of a stable bacterial load and number of inflammatory cells in the lung. In order to follow the inflammatory response during the chronic stage of infection, mice were infected by the aerosol route with M. tuberculosis, and at various time points after exposure, the bacterial load and the total number of cells recovered from individual lungs were enumerated and analyzed by flow cytometry for CD4+and CD8+ T cells. As expected, after the initial exponential growth phase, a stable bacterial load and homeostatic maintenance of inflammatory cells in the lung were observed through 150 days of the experiment (Fig. 1A and B). The numbers of CD4+ T cells that could be isolated from the infected lungs increased up to 90 days postinfection (P = 0.01), while a smaller increase in CD8+ T cells was observed (Fig. 1C and D). IHC analysis of lung granulomas 90 days postinfection corroborated the flow results showing a prevalence of CD4 cells that were both surrounding and within the lesions (Fig. 1E), while CD8+ cells were sparsely distributed around the perimeter of the granuloma (Fig. 1F), as has been previously observed (11).
|
|
|
, and its production is directly correlated with protection in the mouse model (6, 7). In addition, however, both innate and acquired mechanisms induced by pulmonary tuberculosis can drive the production of this cytokine (4, 7, 13-14, 20). As shown in Fig. 4A, an increase in CD4 T cells secreting IFN-
was observed up to the 90-day time point, and a smaller, yet still significant, increase was seen within the CD8 cell population (Fig. 4B). In both cases, cells producing this cytokine were predominately from within the effector T-cell subsets.
|
. These results are fully consistent with the recent hypothesis put forth by Bevan (2) that chronic diseases such as tuberculosis and leprosy probably create a state of immunity characterized by the continuous presence of effector T cells. This process is probably driven by antigen, because prolonged chemotherapy which clears M. tuberculosis leads to the establishment of memory immunity (1, 13, 20). If such a hypothesis is correct, then it implies that the persisting bacteria produce sufficient antigen to maintain the lung immune response in a state of effector immunity and argues against the notion that bacteria present at this time are in some state of latency. It is not known at this point if CD4 T cells in a state of memory immunity control challenge infections directly or whether they must first revert to effector cells. Since the bacteria are contained but not cleared in animal vaccination models of tuberculosis, one must assume that prolonged control of persistent low-level infection in such models requires the sustained presence of effector T cells. One must also assume that initially establishing a population of antigen-specific memory T cells is the most efficient way to achieve this outcome, but it may also be predicated on efficient transition to a more protective phenotype, as recent results from Andersen and Smedegaard (1) tend to suggest. To complicate matters even further, the CD62Llow populations probably include some cells in a state of memory immunity (3). These findings may provide new strategies for rational tuberculosis vaccine design efforts (21).
| ACKNOWLEDGMENTS |
|---|
We thank Angelo Izzo and Todd Lasco for revising the text.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Andersen, P., and B. Smedegaard. 2000. CD4+ T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect. Immun. 68:621-629. |
| 2. | Bevan, M. J. 2002. Immunology: remembrance of things past. Nature 420:748-749.[CrossRef][Medline] |
| 3. | Blander, J. M., D. B. Sant'Angelo, D. Metz, S. Kim, R. A. Flavell, K. Bottomly, and C. A. Janeway, Jr. 2003. A pool of central memory-like CD4 T cells contains effector memory precursors. J. Immunol. 170:2940-2948. |
| 4. | Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. B. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736. |
| 5. | Cooper, A. M., J. E. Callahan, M. Keen, J. T. Belisle, and I. M. Orme. 1997. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tuber. Lung Dis. 78:67-73.[CrossRef][Medline] |
| 6. | Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247. |
| 7. | Cooper, A. M., and J. L. Flynn. 1995. The protective immune response to Mycobacterium tuberculosis. Curr. Opin. Immunol. 7:512-516.[CrossRef][Medline] |
| 8. | Dolin, P. J., M. C. Raviglione, and A. Kochi. 1994. Global tuberculosis incidence and mortality during 1990-2000. Bull. W. H. O. 72:213-220.[Medline] |
| 9. | Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.[CrossRef][Medline] |
| 10. | Flynn, J. L., and J. Chan. 2001. Tuberculosis: latency and reactivation. Infect. Immun. 69:4195-4201. |
| 11. | Gonzalez-Juarrero, M., O. C. Turner, J. Turner, P. Marietta, J. V. Brooks, and I. M. Orme. 2001. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69:1722-1728. |
| 12. | Gonzalez-Juarrero, M., T. S. Shim, A. Kipnis, A. P. Junqueira-Kipnis, and I. M. Orme. 2003. Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J. Immunol. 171:3128-3135. |
| 13. | Griffin, J. P., and I. M. Orme. 1994. Evolution of CD4 T-cell subsets following infection of naive and memory immune mice with Mycobacterium tuberculosis. Infect. Immun. 62:1683-1690. |
| 14. | Heldwein, K. A., and M. J. Fenton. 2002. The role of Toll-like receptors in immunity against mycobacterial infection. Microbes Infect. 4:937-944.[CrossRef][Medline] |
| 15. | Kaech, S. M., S. Hemby, E. Kersh, and R. Ahmed. 2002. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851.[CrossRef][Medline] |
| 16. | Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.[CrossRef][Medline] |
| 17. | Kooyk, Y., B. Appelmelk, and T. B. Geijtenbeek. 2003. A fatal attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance. Trends Mol. Med. 9:153-159.[CrossRef][Medline] |
| 18. | Manabe, Y. C., and W. R. Bishai. 2000. Latent Mycobacterium tuberculosis--persistence, patience, and winning by waiting. Nat. Med. 6:1327-1329.[CrossRef][Medline] |
| 19. | Orme, I. M. 2003. The mouse as a useful model of tuberculosis. Tuberculosis (Edinb). 83:112-115. |
| 20. | Orme, I. M., P. Andersen, and W. H. Boom. 1993. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 167: 1481-1497.[Medline] |
| 21. | Orme, I. M., D. N. McMurray, and J. T. Belisle. 2001. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9:115-118.[CrossRef][Medline] |
| 22. | Orme, M. 2001. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int. J. Tuberc. Lung Dis. 5:589-593.[Medline] |
| 23. | Parrish, N. M., J. D. Dick, and W. R. Bishai. 1998. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6:107-112.[CrossRef][Medline] |
| 24. | Raviglione, M. C., D. E. Snider, Jr., and A. Kochi. 1995. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 273:220-226.[Abstract] |
| 25. | Rhoades, E. R., A. A. Frank, and I. M. Orme. 1997. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung Dis. 78:57-66.[CrossRef][Medline] |
| 26. | Winslow, G. M., A. D. Roberts, M. A. Blackman, and D. L. Woodland. 2003. Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse. J. Immunol. 170:2046-2052. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|